Cancer Research
Technology (CRT) has announced that it has signed a deal to develop a treatment
called Antibody Drug Conjugates (ADCs).
The work will involve using the organisation's own antibodies and peptides in
combination with ADC Therapeutics Sarl's 'warhead' and linker chemistries.
ADCs are an exciting development because they use the specificity associated
with antibodies to allow powerful tumour-destroying chemicals to be internalised
inside the cancer cell and avoid the surrounding healthy tissue, states the company.
Dr Phil L'Huillier, CRT's director of business management, believes this
combination has already shown "promising evidence" and could be an
important cancer treatment in the future.
"We hope the collaboration will identify a range of ADCs that can be taken
forward for development into innovative new ways to treat cancer and save
lives," he said.
According to Cancer Research UK, around 880 people are diagnosed with the
disease every day in the UK.
© Adfero Ltd
Cancer treatment news : 10 July 2012
